Carvykti Significantly Improves Overall Survival in Relapsed Multiple Myeloma in Phase III Trial
Carvykti (ciltacabtagene autoleucel) was found to produce a significant improvement in overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma, according to long-term data from the Phase III CARTITUDE-4 (NCT04181827) …